- Home
- ATYR vs MG Comparison
ATYR vs MG Comparison
Compare ATYR & MG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATYR | MG |
|---|---|---|
| Founded | 2005 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Military/Government/Technical |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.8M | 531.0M |
| IPO Year | 2015 | 2008 |
Fundamental Metrics
Financial Performance| Metric | ATYR | MG |
|---|---|---|
| Price | $0.50 | $18.96 |
| Analyst Decision | Hold | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $3.67 | N/A |
| AVG Volume (30 Days) | ★ 679.8K | 200.0K |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.98 | N/A |
| EPS | N/A | ★ 0.30 |
| Revenue | $190,000.00 | ★ $700,970,000.00 |
| Revenue This Year | N/A | $5.47 |
| Revenue Next Year | N/A | $3.59 |
| P/E Ratio | ★ N/A | $65.03 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.40 | $9.35 |
| 52 Week High | $6.50 | $20.20 |
Technical Indicators
Market Signals| Indicator | ATYR | MG |
|---|---|---|
| Relative Strength Index (RSI) | 49.09 | 64.90 |
| Support Level | $0.46 | $13.37 |
| Resistance Level | $0.60 | $19.30 |
| Average True Range (ATR) | 0.04 | 0.95 |
| MACD | 0.00 | 0.35 |
| Stochastic Oscillator | 24.55 | 76.51 |
Price Performance
Historical ComparisonAbout ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
About MG Mistras Group Inc
MISTRAS Group Inc provides asset protection solutions and systems. The company evaluates the structural integrity and reliability of critical energy, industrial, and public infrastructure. The company's three operating segments are North America, International, and Products and Systems, of which key revenue is derived from the North America segment. The North America segment provides asset protection solutions, including NDT, inspection, and mechanical and engineering services, along with software, digital, and data services.